Literature DB >> 8947928

Effects of opioids on the immune system.

S Roy1, H H Loh.   

Abstract

Both therapeutic and chronic uses of opioids compromise the optimal functioning of the immune system. Overwhelming evidence suggests that opioid use affects both innate immunity and adaptive immunity. Chronic administration of opioids decreases the proliferative capacity of macrophage progenitor cells and lymphocytes. Additionally, the differentiated function of immune cells is significantly affected by opioids. These effects are mediated by either a direct action of opioids on the target cells or by indirect centrally mediated pathways. Molecular biological and biochemical characterization suggest that immune cells differentially express classical opioid receptors. Interestingly, these studies also reveal the presence of a novel class of opioid receptors in immune cells. We believe that this low affinity morphine binding site mediates the antiproliferative effects of morphine.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8947928     DOI: 10.1007/bf02532379

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  66 in total

1.  Characterization of [3H]morphine binding to interleukin-1-activated thymocytes.

Authors:  S Roy; B L Ge; H H Loh; N M Lee
Journal:  J Pharmacol Exp Ther       Date:  1992-11       Impact factor: 4.030

2.  Gene expression and localization of opioid peptides in immune cells of inflamed tissue: functional role in antinociception.

Authors:  R Przewłocki; A H Hassan; W Lason; C Epplen; A Herz; C Stein
Journal:  Neuroscience       Date:  1992       Impact factor: 3.590

3.  Complementary DNA cloning of a mu-opioid receptor from rat peritoneal macrophages.

Authors:  M Sedqi; S Roy; S Ramakrishnan; R Elde; H H Loh
Journal:  Biochem Biophys Res Commun       Date:  1995-04-17       Impact factor: 3.575

Review 4.  Mechanisms of morphine-induced immunomodulation.

Authors:  P K Peterson; T W Molitor; C C Chao
Journal:  Biochem Pharmacol       Date:  1993-08-03       Impact factor: 5.858

5.  Morphine-induced alterations of immune status: dose dependency, compartment specificity and antagonism by naltrexone.

Authors:  D T Lysle; M E Coussons; V J Watts; E H Bennett; L A Dykstra
Journal:  J Pharmacol Exp Ther       Date:  1993-06       Impact factor: 4.030

6.  Spleen and thymus cell subsets modified by long-term morphine administration and murine AIDS--II.

Authors:  M C Lopez; G J Chen; L L Colombo; D S Huang; H R Darban; B Watzl; R R Watson
Journal:  Int J Immunopharmacol       Date:  1993-11

7.  beta-Endorphin augments the cytolytic activity and interferon production of natural killer cells.

Authors:  R N Mandler; W E Biddison; R Mandler; S A Serrate
Journal:  J Immunol       Date:  1986-02-01       Impact factor: 5.422

8.  Morphine inhibits spontaneous and cytokine-enhanced natural killer cell cytotoxicity in volunteers.

Authors:  M P Yeager; T A Colacchio; C T Yu; L Hildebrandt; A L Howell; J Weiss; P M Guyre
Journal:  Anesthesiology       Date:  1995-09       Impact factor: 7.892

9.  Inhibition of interleukin-1 and tumor necrosis factor-alpha synthesis following treatment of macrophages with the kappa opioid agonist U50, 488H.

Authors:  S M Belkowski; C Alicea; T K Eisenstein; M W Adler; T J Rogers
Journal:  J Pharmacol Exp Ther       Date:  1995-06       Impact factor: 4.030

10.  Effects of naltrexone on morphine-induced tolerance and physical dependence and changes in cellular immune function in mice.

Authors:  H N Bhargava; R V House; S N Thorat; P T Thomas
Journal:  Brain Res       Date:  1995-08-28       Impact factor: 3.252

View more
  36 in total

1.  Galpha(14) links a variety of G(i)- and G(s)-coupled receptors to the stimulation of phospholipase C.

Authors:  M K Ho; L Y Yung; J S Chan; J H Chan; C S Wong; Y H Wong
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

Review 2.  Modulation of immune function by morphine: implications for susceptibility to infection.

Authors:  Sabita Roy; Jinghua Wang; Jennifer Kelschenbach; Lisa Koodie; Josephine Martin
Journal:  J Neuroimmune Pharmacol       Date:  2006-03       Impact factor: 4.147

Review 3.  Drugs of abuse, immune modulation, and AIDS.

Authors:  Guy A Cabral
Journal:  J Neuroimmune Pharmacol       Date:  2006-06-28       Impact factor: 4.147

Review 4.  Proteases for processing proneuropeptides into peptide neurotransmitters and hormones.

Authors:  Vivian Hook; Lydiane Funkelstein; Douglas Lu; Steven Bark; Jill Wegrzyn; Shin-Rong Hwang
Journal:  Annu Rev Pharmacol Toxicol       Date:  2008       Impact factor: 13.820

Review 5.  Opioid pharmaceuticals and addiction: the issues, and research directions seeking solutions.

Authors:  Wendy M Walwyn; Karen A Miotto; Christopher J Evans
Journal:  Drug Alcohol Depend       Date:  2010-02-25       Impact factor: 4.492

6.  Abolition of morphine-immunosuppression in mice lacking the mu-opioid receptor gene.

Authors:  C Gavériaux-Ruff; H W Matthes; J Peluso; B L Kieffer
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

7.  Opiates and the development of post-injury complications: a review.

Authors:  Martin G Schwacha
Journal:  Int J Clin Exp Med       Date:  2008-01-20

8.  Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain.

Authors:  Roger Chou; Gilbert J Fanciullo; Perry G Fine; Jeremy A Adler; Jane C Ballantyne; Pamela Davies; Marilee I Donovan; David A Fishbain; Kathy M Foley; Jeffrey Fudin; Aaron M Gilson; Alexander Kelter; Alexander Mauskop; Patrick G O'Connor; Steven D Passik; Gavril W Pasternak; Russell K Portenoy; Ben A Rich; Richard G Roberts; Knox H Todd; Christine Miaskowski
Journal:  J Pain       Date:  2009-02       Impact factor: 5.820

9.  Rhesus macaque model of chronic opiate dependence and neuro-AIDS: longitudinal assessment of auditory brainstem responses and visual evoked potentials.

Authors:  Mariam Riazi; Joanne K Marcario; Frank K Samson; Himanshu Kenjale; Istvan Adany; Vincent Staggs; Emily Ledford; Janet Marquis; Opendra Narayan; Paul D Cheney
Journal:  J Neuroimmune Pharmacol       Date:  2009-03-13       Impact factor: 4.147

Review 10.  Chronic opioid therapy in long-term cancer survivors.

Authors:  A Carmona-Bayonas; P Jiménez-Fonseca; E Castañón; A Ramchandani-Vaswani; R Sánchez-Bayona; A Custodio; D Calvo-Temprano; J A Virizuela
Journal:  Clin Transl Oncol       Date:  2016-07-21       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.